

# Nicholas Finer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8362952/nicholas-finer-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179  
papers

9,754  
citations

51  
h-index

96  
g-index

217  
ext. papers

11,049  
ext. citations

6.5  
avg, IF

5.98  
L-index

#	Paper	IF	Citations
179	Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> ,	6.7	4
178	Future directions in obesity pharmacotherapy. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 93, 13-20	3.9	6
177	Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli database. <i>Obesity Science and Practice</i> , <b>2021</b> , 7, 148-158	2.6	
176	A comprehensive descriptive assessment of obesity related chronic morbidity and estimated annual cost burden from a population-based electronic health record database. <i>Israel Journal of Health Policy Research</i> , <b>2020</b> , 9, 32	1.7	2
175	Response to Does smoking or alcohol cause early vascular damage in teenage years? <i>European Heart Journal</i> , <b>2019</b> , 40, 3497	9.5	
174	Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. <i>The Lancet Child and Adolescent Health</i> , <b>2019</b> , 3, 474-481	14.5	25
173	Letter to the Editor regarding Mocanu et al. Ongoing Inconsistencies in Weight Loss Reporting Following Bariatric Surgery: a Systematic Review. <i>Obesity Surgery</i> <a href="https://doi.org/10.1007/s11695-018-03702-6">https://doi.org/10.1007/s11695-018-03702-6</a> Mocanu. <i>Obesity Surgery</i> , <b>2019</b> , 29, 1942	3.7	
172	Early vascular damage from smoking and alcohol in teenage years: the ALSPAC study. <i>European Heart Journal</i> , <b>2019</b> , 40, 345-353	9.5	25
171	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia	1.9	48
170	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 1441-1455	1.9	26
169	The effects of Ramadan fasting on activity and energy expenditure. <i>American Journal of Clinical Nutrition</i> , <b>2018</b> , 107, 54-61	7	33
168	Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. <i>Diabetic Medicine</i> , <b>2018</b> , 35, 360-367	3.5	58
167	Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. <i>Obesity Reviews</i> , <b>2018</b> , 19, 14-27	10.6	23
166	Assessing the causal role of body mass index on cardiovascular health in young adults: Mendelian randomization and recall-by-genotype analyses. <i>Circulation</i> , <b>2018</b> , 138, 2187-2201	16.7	34
165	Pre-pregnancy weight loss in women with obesity requesting removal of their intra-uterine contraceptive device in order to conceive: a pilot study of full meal replacement. <i>Clinical Obesity</i> , <b>2018</b> , 8, 244-249	3.6	6
164	Periodontal complications with obesity. <i>Periodontology 2000</i> , <b>2018</b> , 78, 98-128	12.9	46
163	Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 144-151	1.9	5

162	The Impact of Diet-Induced Weight Loss on Biomarkers for Colorectal Cancer: An Exploratory Study (INTERCEPT). <i>Obesity</i> , <b>2017</b> , 25 Suppl 2, S95-S101	8	10
161	Can we reconcile the obesity paradox with recent cardiovascular outcome trials in diabetes?. <i>Clinical Obesity</i> , <b>2017</b> , 7, 255-259	3.6	1
160	Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 118-124	6.7	8
159	Interdisciplinary European guidelines on metabolic and bariatric surgery. <i>Gastroenterologie A Hepatologie</i> , <b>2017</b> , 71, 487-500	1.4	5
158	Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2017</b> , 3, 134-139	6.4	2
157	Direct ophthalmoscopy should be taught to undergraduate medical students. <i>Eye</i> , <b>2016</b> , 30, 497	4.4	4
156	NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. <i>Obesity Surgery</i> , <b>2016</b> , 26, 649-59	3.7	29
155	Defining the role of metabolic physician <b>2016</b> , 171-181		
154	Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. <i>Obesity Reviews</i> , <b>2016</b> , 17, 1001-11	10.6	90
153	Drug interventions for the treatment of obesity in children and adolescents. <i>The Cochrane Library</i> , <b>2016</b> , 11, CD012436	5.2	42
152	Obesity Management in Europe: Current Status and Objectives for the Future. <i>Obesity Facts</i> , <b>2016</b> , 9, 273-83	5.1	13
151	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1678-88	1.9	8
150	Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: Effect of gender, type 2 diabetes and relationship to post-operative weight loss. <i>Appetite</i> , <b>2016</b> , 107, 93-105	4.5	55
149	Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation. <i>Journal of Intellectual Disability Research</i> , <b>2016</b> , 60, 149-55	3.2	25
148	Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2015</b> , 29, 1484-91	5.2	77
147	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , <b>2015</b> , 39, 849-57	5.5	5
146	Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 425-34	1.9	22
145	Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. <i>Clinical Obesity</i> , <b>2015</b> , 5, 245-55	3.6	9

144	A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , <b>2015</b> , 2015, 150020	1.4	6
143	Feasibility and Impact of a Combined Supervised Exercise and Nutritional-Behavioral Intervention following Bariatric Surgery: A Pilot Study. <i>Journal of Obesity</i> , <b>2015</b> , 2015, 693829	3.7	19
142	New medications for treatment of obesity: metabolic and cardiovascular effects. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 142-52	3.8	41
141	Medical consequences of obesity. <i>Medicine</i> , <b>2015</b> , 43, 88-93	0.6	21
140	Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. <i>International Journal of Obesity</i> , <b>2014</b> , 38, 1165-71	5.5	21
139	Pharmacotherapy for obesity: novel agents and paradigms. <i>Therapeutic Advances in Chronic Disease</i> , <b>2014</b> , 5, 135-48	4.9	68
138	Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2014</b> , 24, 656-62	4.5	20
137	Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 648-54	18.1	62
136	Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. <i>International Journal of Obesity</i> , <b>2014</b> , 38, 689-97	5.5	110
135	Comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. <i>Diabetes Care</i> 2014;37:2108-2113. <i>Diabetes Care</i> , <b>2014</b> , 37, e265	14.6	1
134	Sarcopenic obesity: under recognised and over treated?. <i>Clinical Medicine</i> , <b>2014</b> , 14, 454	1.9	
133	Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. <i>Obesity</i> , <b>2014</b> , 22, 2137-46	8	35
132	Clinical pictures. <i>Clinical Obesity</i> , <b>2014</b> , 4, 125-6	3.6	
131	Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 1178-88	1.9	47
130	Age- and sex-specific effects on weight loss outcomes in a comparison of sleeve gastrectomy and Roux-en-Y gastric bypass: a retrospective cohort study. <i>BMC Obesity</i> , <b>2014</b> , 1, 12	3.6	13
129	Obesity and difficult-to-treat arterial hypertension. <i>Clinical Obesity</i> , <b>2014</b> , 4, 59-60	3.6	1
128	Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. <i>International Journal of Obesity</i> , <b>2014</b> , 38, 432-7	5.5	18
127	Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. <i>Obesity Surgery</i> , <b>2014</b> , 24, 241-52	3.7	179

126	Latent autoimmune diabetes in adults presenting as diabetes "recurrence" after bariatric surgery: a case report. <i>Diabetes Care</i> , <b>2013</b> , 36, e120	14.6	7
125	Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 3746-53	14.6	17
124	Drug treatment of obesity in the cardiovascular patient. <i>Current Opinion in Cardiology</i> , <b>2013</b> , 28, 584-91	2.1	2
123	The impact of a health professional recommendation on weight loss attempts in overweight and obese British adults: a cross-sectional analysis. <i>BMJ Open</i> , <b>2013</b> , 3, e003693	3	71
122	Act now against new NHS competition regulations: an open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations. <i>BMJ, The</i> , <b>2013</b> , 346, f1819	5.9	3
121	Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. <i>British Journal of General Practice</i> , <b>2013</b> , 63, e115-24	1.6	58
120	Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. <i>PLoS ONE</i> , <b>2013</b> , 8, e59121	3.7	40
119	Weight Management: Approaches <b>2013</b> , 404-409		1
118	Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 523-30	6.7	102
117	Childhood obesity and vascular phenotypes: a population study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 2643-50	15.1	93
116	Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. <i>Diabetologia</i> , <b>2012</b> , 55, 2348-55	10.3	49
115	Drug treatment of obesity in cardiovascular disease. <i>American Journal of Cardiovascular Drugs</i> , <b>2012</b> , 12, 93-104	4	12
114	Selenium supplementation and exercise: effect on oxidant stress in overweight adults. <i>Obesity</i> , <b>2012</b> , 20, 794-801	8	20
113	The implementation of the Counterweight Programme in Scotland, UK. <i>Family Practice</i> , <b>2012</b> , 29 Suppl 1, i139-i144	1.9	18
112	Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. <i>International Journal of Obesity</i> , <b>2012</b> , 36, 843-54	5.5	408
111	Adipose and height growth through childhood and blood pressure status in a large prospective cohort study. <i>Hypertension</i> , <b>2012</b> , 59, 919-25	8.5	71
110	Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. <i>European Journal of Endocrinology</i> , <b>2012</b> , 166, 951-5	6.5	53
109	Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. <i>Obesity Facts</i> , <b>2012</b> , 5, 460-83	5.1	171

108	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 1047-55	1.9	95
107	Outcomes of an adolescent bariatric service. <i>Archives of Disease in Childhood</i> , <b>2012</b> , 97, A63.1-A63	2.2	2
106	Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine. <i>Journal of Obesity</i> , <b>2011</b> , 2011,	3.7	2
105	Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. <i>Obesity</i> , <b>2011</b> , 19, 1404-14	8	22
104	Medical consequences of obesity. <i>Medicine</i> , <b>2011</b> , 39, 18-23	0.6	8
103	Criteria for EASO-collaborating centres for obesity management. <i>Obesity Facts</i> , <b>2011</b> , 4, 329-33	5.1	25
102	Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. <i>Value in Health</i> , <b>2010</b> , 13, 402-10	3.3	12
101	Long-term cost-effectiveness of weight management in primary care. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 775-83	2.9	55
100	Counterweight - counter-cost, counter-loss. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 828-9	2.9	
99	Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. <i>Obesity</i> , <b>2010</b> , 18, 391-6	8	19
98	Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. <i>Obesity</i> , <b>2010</b> , 18, 987-94	8	13
97	Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 26-34	6.7	14
96	EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, A141.E1326	15.1	3
95	Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. <i>European Heart Journal</i> , <b>2010</b> , 31, 3063-72	9.5	113
94	Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 905-17	59.2	627
93	Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>2010</b> , 99, 673-678	3.1	52
92	The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. <i>BMC Endocrine Disorders</i> , <b>2010</b> , 10, 3	3.3	9
91	Withdrawal of sibutramine. Editorial in judgment in advance of the facts. <i>BMJ, The</i> , <b>2010</b> , 340, c1346	5.9	6

90	Oxidant stress in healthy normal-weight, overweight, and obese individuals. <i>Obesity</i> , <b>2009</b> , 17, 460-6	8	53
89	Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 239-50	6.7	22
88	Obesity remains under diagnosed in English hospital in-patients. <i>Obesity Research and Clinical Practice</i> , <b>2009</b> , 3, 1-52	5.4	4
87	Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. <i>Metabolism: Clinical and Experimental</i> , <b>2009</b> , 58, 1109-15	12.7	56
86	Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. <i>Nutrition and Metabolism</i> , <b>2009</b> , 6, 42	4.6	8
85	Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , <b>2009</b> , 374, 1606-16	40	741
84	Validation of a quantitative magnetic resonance method for measuring human body composition. <i>Obesity</i> , <b>2008</b> , 16, 191-8	8	63
83	PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 1248-60	6.7	12
82	The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change. <i>Obesity Research and Clinical Practice</i> , <b>2008</b> , 2, I-II	5.4	19
81	Management of obesity in adults: European clinical practice guidelines. <i>Obesity Facts</i> , <b>2008</b> , 1, 106-16	5.1	241
80	The metabolic profile of early Huntington <sup>®</sup> disease--a combined human and transgenic mouse study. <i>Experimental Neurology</i> , <b>2008</b> , 210, 691-8	5.7	89
79	Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 498-505	6.7	25
78	Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. <i>Family Practice</i> , <b>2008</b> , 25 Suppl 1, i79-86	1.9	15
77	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2008</b> , 8, 170-176		1
76	Interdisciplinary European guidelines on surgery of severe obesity. <i>Obesity Facts</i> , <b>2008</b> , 1, 52-9	5.1	105
75	Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. <i>Journal of Cardiovascular Pharmacology</i> , <b>2008</b> , 52, 393-402	3.1	18
74	Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. <i>British Journal of General Practice</i> , <b>2008</b> , 58, 548-54	1.6	151
73	The clinical effectiveness of weight loss drugs. <i>Obesity Research and Clinical Practice</i> , <b>2007</b> , 1, 1-78	5.4	11

72	Inter-disciplinary European guidelines on surgery of severe obesity. <i>International Journal of Obesity</i> , <b>2007</b> , 31, 569-77	5.5	151
71	Interdisciplinary European guidelines for surgery for severe (morbid) obesity. <i>Obesity Surgery</i> , <b>2007</b> , 17, 260-70	3.7	122
70	The comparative effects of bariatric surgery on weight and type 2 diabetes. <i>Obesity Surgery</i> , <b>2007</b> , 17, 1248-56	3.7	49
69	Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. <i>European Heart Journal</i> , <b>2007</b> , 28, 2915-23	9.5	109
68	Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. <i>Growth Hormone and IGF Research</i> , <b>2007</b> , 17, 67-76	2	22
67	Rimonabant in obese patients with type 2 diabetes [Authors Reply]. <i>Lancet, The</i> , <b>2007</b> , 369, 554-555	4.0	0
66	Drug treatments for obesity. <i>Lancet, The</i> , <b>2007</b> , 369, 1163; author reply 1164	4.0	1
65	The comparative effects of bariatric surgery on weight and type 2 diabetes. <i>Obesity Surgery</i> , <b>2007</b> , 17, 1248-1256	3.7	
64	ABC of obesity. Management: part II--drugs. <i>BMJ, The</i> , <b>2006</b> , 333, 794-7	5.9	28
63	Psychiatric co-morbidities in patients attending specialist obesity services in the UK. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2006</b> , 99, 317-25	2.7	53
62	Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. <i>Diabetes</i> , <b>2006</b> , 55, 1327-36	0.9	131
61	Obesity and risk of myocardial infarction: the INTERHEART study. <i>Lancet, The</i> , <b>2006</b> , 367, 1053	4.0	5
60	Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. <i>Lancet, The</i> , <b>2006</b> , 368, 1660-72	4.0	624
59	Medical consequences of obesity. <i>Medicine</i> , <b>2006</b> , 34, 510-514	0.6	13
58	Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2006</b> , 8, 206-13	6.7	51
57	The EAES Clinical Practice Guidelines on Obesity Surgery (2005) <b>2006</b> , 213-257		0
56	Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. <i>Country Review Ukraine</i> , <b>2005</b> , 7, L32-L38		6
55	Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 439-47	6.7	30



54	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 755-61	6.7	97
53	Empowering primary care to tackle the obesity epidemic: the Counterweight Programme. <i>European Journal of Clinical Nutrition</i> , <b>2005</b> , 59 Suppl 1, S93-100; discussion S101	5.2	46
52	Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the Darwin study. <i>Diabetologia</i> , <b>2005</b> , 48, 222-9	10.3	26
51	Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2005</b> , 19, 200-21	5.2	294
50	Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2005</b> , 5, 121-124		8
49	Rationing joint replacements: trust decision seems to be based on prejudice or attributing blame. <i>BMJ, The</i> , <b>2005</b> , 331, 1472	5.9	10
48	Aspartame and its effects on health: approach seems simplistic in electronic responses to editorial. <i>BMJ, The</i> , <b>2005</b> , 330, 310; author reply 310	5.9	
47	Atlas of Obesity and Weight Control. <i>Clinical Endocrinology</i> , <b>2004</b> , 60, 150-150	3.4	
46	A new evidence-based model for weight management in primary care: the Counterweight Programme. <i>Journal of Human Nutrition and Dietetics</i> , <b>2004</b> , 17, 191-208	3.1	98
45	Current approaches to obesity management in UK Primary Care: the Counterweight Programme. <i>Journal of Human Nutrition and Dietetics</i> , <b>2004</b> , 17, 183-90	3.1	72
44	Obesity. <i>Clinical Medicine</i> , <b>2003</b> , 3, 23-7	1.9	27
43	Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 78, 209-14	7	58
42	Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. <i>Breast</i> , <b>2003</b> , 12, 290-3	3.6	89
41	Moderate exercise and fibrinolytic potential in obese sedentary men with metabolic syndrome. <i>Obesity</i> , <b>2003</b> , 11, 1333-8		9
40	Changes in risk factors for cardiovascular disease with body fat loss in obese women. <i>Diabetes, Obesity and Metabolism</i> , <b>2002</b> , 4, 379-87	6.7	26
39	Sibutramine: its mode of action and efficacy. <i>International Journal of Obesity</i> , <b>2002</b> , 26 Suppl 4, S29-33	5.5	48
38	A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 348-54	2.4	155
37	Pharmacotherapy of obesity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 16, 717-42	6.5	38

36	The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss. <i>Eating Behaviors</i> , <b>2002</b> , 3, 275-84	3	12
35	Low-calorie diets and sustained weight loss. <i>Obesity</i> , <b>2001</b> , 9 Suppl 4, 290S-294S		29
34	Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. <i>International Journal of Obesity</i> , <b>2001</b> , 25, 496-501	5.5	81
33	Is obesity a disease?. <i>International Journal of Obesity</i> , <b>2001</b> , 25, 1401-4	5.5	62
32	Reply: Is obesity a disease?. <i>International Journal of Obesity</i> , <b>2001</b> , 25, 1405-6	5.5	17
31	Sibutramine in clinical practice. <i>International Journal of Obesity</i> , <b>2001</b> , 25 Suppl 4, S12-5	5.5	3
30	Drug therapy for management of obesity. <i>Lancet, The</i> , <b>2001</b> , 357, 1288	4.0	
29	THE EFFECT OF MODERATE EXERCISE ON PLASMINOGEN ACTIVATOR INHIBITOR IN OBESE VS NON OBESE SEDENTARY MALES. <i>Medicine and Science in Sports and Exercise</i> , <b>2001</b> , 33, S78	1.2	
28	Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , <b>2000</b> , 2, 105-12	6.7	148
27	Redefining type 2 diabetes: Obesity or obesity dependent diabetes mellitus?. <i>Obesity Reviews</i> , <b>2000</b> , 1, 57-9	10.6	277
26	One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. <i>International Journal of Obesity</i> , <b>2000</b> , 24, 306-13	5.5	217
25	Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. <i>Lancet, The</i> , <b>2000</b> , 356, 2119-25	4.0	657
24	Prevention and management of obesity: pharmacology. <i>Proceedings of the Nutrition Society</i> , <b>2000</b> , 59, 413	2.9	
23	The Cost of Obesity in the United Kingdom. <i>Journal of Medical Economics</i> , <b>1999</b> , 2, 143-153	2.4	3
22	WEIGHT MANAGEMENT   Approaches* <b>1998</b> , 407-413		
21	Present and future pharmacological approaches. <i>British Medical Bulletin</i> , <b>1997</b> , 53, 409-32	5.4	28
20	Two cases of Wegener's granulomatosis involving the pituitary. <i>Clinical Endocrinology</i> , <b>1995</b> , 42, 323-8	3.4	36
19	Serotonergic system: therapeutic implications in obesity. <i>Acta Clinica Belgica</i> , <b>1992</b> , 14, 47-51	1.8	1

18	Drug therapy after very-low-calorie diets. <i>American Journal of Clinical Nutrition</i> , <b>1992</b> , 56, 195S-198S	7	18
17	Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection. <i>Journal of the Royal Society of Medicine</i> , <b>1992</b> , 85, 530-3	2.3	3
16	Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine <b>1989</b> , 13 Suppl 2, 91-3		3
15	Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. <i>Metabolism: Clinical and Experimental</i> , <b>1988</b> , 37, 672-6	12.7	69
14	Prediction of Resting Metabolic Rate in Man by Bio-Impedance Analysis [Bia]. <i>Clinical Science</i> , <b>1988</b> , 74, 2P-2P		
13	The effect of enkephalin analogue on pituitary hormone release in human obesity. <i>Hormone and Metabolic Research</i> , <b>1987</b> , 19, 68-70	3.1	17
12	Very Low Calorie Diet and Noradrenaline-Induced Thermogenesis in Human Obesity. <i>Clinical Science</i> , <b>1987</b> , 73, 17P-17P		
11	Prolonged weight loss with dexfenfluramine treatment in obese patients. <i>Diabète &amp; Métabolisme</i> , <b>1987</b> , 13, 598-602		8
10	Metabolic rate after massive weight loss in human obesity. <i>Clinical Science</i> , <b>1986</b> , 70, 395-8	6.5	18
9	Responses of neurohypophysial peptides to hypertonic saline and insulin-induced hypoglycaemia in man. <i>Clinical Endocrinology</i> , <b>1986</b> , 24, 97-105	3.4	27
8	The composition of lunch determines afternoon plasma tryptophan ratios in humans. <i>Journal of Neural Transmission</i> , <b>1986</b> , 65, 211-7	4.3	39
7	Do frequent clinic visits improve diabetic control?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , <b>1985</b> , 2, 30-31		
6	Pregnancy in a woman with premature ovarian failure. <i>Postgraduate Medical Journal</i> , <b>1985</b> , 61, 1079-80	2	16
5	Pituitary infarction and development of the empty sella syndrome after gastrointestinal haemorrhage. <i>British Medical Journal</i> , <b>1984</b> , 289, 661-2		8
4	Metergoline as an alternative to bromocriptine in amenorrhoea. <i>European Journal of Endocrinology</i> , <b>1984</b> , 107, 439-44	6.5	1
3	Mammary gigantism and D-penicillamine. <i>Clinical Endocrinology</i> , <b>1984</b> , 21, 219-22	3.4	7
2	Diet and Noradrenaline Induced Thermogenesis in Massive Obesity. <i>Clinical Science</i> , <b>1983</b> , 65, 23P-23P	6.5	2
1	Assessing the causal role of body mass index on cardiovascular health in young adults: Mendelian randomization and recall-by-genotype analyses		3

